Figure 1.
Therapeutic effects of MVA vaccines in CT26 colon cancer tumor models. BALB/c mice were IV injected (caudal vein) with either 2 × 105 CT26.CL25 (A) or CT26-MUC1 (B) cells. On day 2 and 9 after tumor challenge, mice were treated either with 1 × 104 pfu of MVA-βgal (A) or 5 × 107 pfu of TG4010 (B). An empty MVA vector was used as control in both models at the same dose. Mice were weighed twice per week and sacrificed when reaching 10% weight loss. Two to three independent experiments were carried out with groups of 10 to 15 mice per group. Overall survival rates represented as Kaplan-Meier curves were compared with a Log-rank test. Therapeutic treatment with 104 pfu MVA-βGal increased the survival by 18 days, while the treatment withTG4010 augmented the overall survival by 3 days. Animal experiments were conducted in compliance with EU directive 2010/63/EU.